Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France

Journal of Hepatology

Volumn 49, Issue 2, 2008, Pages 175-183

  Deuffic Burban, Sylvie ^a,b   Deltenre, Pierre ^a,c   Louvet, Alexandre ^a   Canva, Valérie ^a   Dharancy, Sebastien ^a   Hollebecque, Antoine ^a   Boitard, Jeanne ^a   Henrion, Jean ^c   Yazdanpanah, Yazdan ^b,d,e   Mathurin, Philippe ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^c Hospital de Jolimont   (Belgium)

^d CENTRE HOSPITALIER DE TOURCOING   (France)

^e UNIV LILLE   (France)

Author keywords

Alcohol; Antiviral therapy; Back calculation; HCV eradication; Hepatocellular carcinoma; Liver disease; Markov model; Screening

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; FRANCE; GENOTYPE; HEPATITIS C; HUMAN; INCIDENCE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

EID: 46149090112     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.04.012     Document Type: Article

References (43)

1. Marcellin P., Pequignot F., Delarocque-Astagneau E., Ganne N., Hillon P., Bovet M., et al. Evidence for high rates of HCV and HBV related mortality in France: a large-scale national survey. J Hepatol 44 (2006) S174
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L.J., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
4. Manns M., McHutchinson J.G., Gordon S., Rustgi V., Shiffman M.L., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
5. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis: effects of dose and duration. Hepatology 24 (1996) 778-789
6. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
7. Dubois F., Desenclos J.C., Mariotte N., Goudeau A., and The Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 25 (1997) 1490-1496
8. Meffre C, Le Strat Y, Delarocque-Astagneau E, Meyer J, Coste D, Steinmetz J. Prevalence of hepatitis C in France, 2003-2004. 41st Annual meeting of the European Association for the Study of the Liver; 2006 April 26-30; Vienna, Austria; 2006. J Hepatol 2006;44:S22.
9. Fartoux L., Degos F., Trepo C., Goria O., Cales P., Tran A., et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 5 (2007) 502-507
10. Valla D.C., Chevallier M., Marcellin P., Payen J.L., Trepo C., Fonck M., et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 29 (1999) 1870-1875
11. Benvegnù L., Chemello L., Noventa F., Fattovich G., Pontisso P., and Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83 (1998) 901-909
12. Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnù L., Mazzella G., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007) 579-587
13. Cammà C., Giunta M., Andreone P., and Craxi{dotless}̀ A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34 (2001) 593-602
14. Hung C.H., Lee C.M., Lu S.N., Wang J.H., Hu T.H., Tung H.D., et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 13 (2006) 409-414
15. Corrao G., and Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27 (1998) 914-919
16. Corrao G., Zambon A., Torchio P., Arico S., LaVecchia C., and diOrio F. Attributable risk for symptomatic liver cirrhosis in Italy. J Hepatol 28 (1998) 608-614
17. Monto A., Patel K., Bostrom A., Pianko S., Pockros P., McHutchison J.G., et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 39 (2004) 826-834
18. Ostapowicz G., Watson K.J.R., Locarnini S.A., and Desmond P.V. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 27 (1998) 1730-1735
19. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
20. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34 (2001) 730-739
21. Roudot-Thoraval F., Bastie A., Pawlotsky J.M., and Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 26 (1997) 485-490
22. Wiley T.E., McCarthy M., Breidi L., and Layden T.J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28 (1998) 805-809
23. Kim W.R., Gross Jr. J.B., Poterucha J.J., Locke III G.R., and Dickson E.R. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology 33 (2001) 201-206
24. Deuffic S., Buffat L., Poynard T., and Valleron A.J. Modeling the hepatitis C virus epidemic in France. Hepatology 29 (1999) 1596-1601
25. Deuffic-Burban S., Wong J.B., Valleron A.-J., Costagliola D., Delfraissy J.F., and Poynard T. Comparing the Public Health burden of chronic hepatitis C and HIV infection in France. J Hepatol 40 (2004) 319-326
26. Groupe d'experts. Alcool - Dommages sociaux, abus et dépendances. Paris: Expertise Collective - Les Editions INSERM; 2003.
27. Martinot-Peignoux M., Roudot-Thoraval F., Mendel I., Coste J., Izopet J., Duverlie G., et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 6 (1999) 435-443
28. Pagliaro L., Peri V., Linea C., Cammà C., Giunta M., and Magrin S. Natural history of chronic hepatitis C. Italian J Gastroenterol Hepatol 31 (1999) 28-44
29. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 (1994) 15-20
30. Serfaty L., Aumaitre H., Chazouilleres O., Bonnand A.M., Rosmorduc O., Poupon R.E., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27 (1998) 1435-1440
31. Degos F., Christidis C., Ganne-Carrié N., Farmachidi J.-P., Degott C., Guettier C., et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47 (2000) 131-136
32. D'Amico G., Garcia-Tsao G., and Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44 (2006) 217-231
33. El-Serag H.B., Mason A.C., and Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33 (2001) 62-65
34. Bourliere M., Ouzan D., Rosenheim M., Doffoel M., Marcellin P., Pawlotsky J.M., et al. Efficacy of peginterferon alpha-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study. Hepatology 46 (2007) 366A
35. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
36. Schalm S.W., Weiland O., Hansen B.E., Milella M., Lai F.Y., Hollander A., et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 117 (1999) 408-413
37. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., Morishima C., Wright E.C., Everson G.T., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126 (2004) 1015-1023
38. Marcellin P., Pequignot F., Delarocque-Astagneau E., Zarski J.P., Ganne N., Hillon P., et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 48 (2008) 200-207
39. Fong KW, Jefferson TH, Suyehiro T, Walton L. SLATEC Common Mathematical Library; 1993. Available from http://www.netlib.org/slatec/guide.
40. Marquardt D. An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 11 (1963) 431-441
41. Amin J., Law M.G., Bartlett M., Kaldor J.M., and Dore G.J. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 368 (2006) 938-945
42. Neal K.R., and on behalf of the Trent Hepatitis C Study Group. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 56 (2007) 1098-1104
43. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-2099.